OVERALL The mission of The Jackson Laboratory Cancer Center (JAXCC) is to discover precise genomic solutions for cancer by making basic discoveries with human impact. Committed to our role as a basic research Cancer Center, we harness our transdisciplinary strengths in complex genetics and functional genomics to achieve this goal. Organized in a single research program, Genetic models for precision cancer medicine, the 53 full members combine the JAXCC's unique capabilities to model human cancers in mice with innovations in genomic and computational analytics of human cancers to attack this broad problem. From RNA biology to chromatin dynamics, from organismal to in silico models of cancer, from panels of genetically diverse strains to humanized mice, from single cell genomics to Patient Derived Xenografts, from genomic engineering technologies to genomic diagnostics?The JAXCC brings advanced technologies to bear on persistent cancer problems through collaborative partnerships with clinical investigators. Since 2013, we achieved unprecedented growth with 22 new members with expertise in immunology, computational biology, genomic technologies, epigenetics, microbiome, tumor microenvironment, and clinical genomics. The Shared Resources (Cancer Model Development Resource, Computational Sciences, Genetic Engineering Technologies, Genome and Single Cell Technologies, and Phenotyping Technologies) provide comprehensive support for this wide range of research. The collaborative environment, access to powerful technologies, and our use of Developmental Funds has yielded significant advances: in the past 5 years, we have more than doubled our funding from NCI and other cancer agencies and increased our overall intra-programmatic grant collaborative rate from 21% to 47%. Our translational impact includes development of therapeutics exploiting genomic instability; our role as a discovery engine for SWOG and our new community cancer genomic education initiative, the Maine Cancer Genomics Initiative. In the next five years, the JAXCC will harness the collective energy of our expanded Cancer Center. We will identify origins and the consequences of complex structural genomic alterations in cancer; we will craft genetically complex models of cancer to uncover the systems biology of the disease; we will explore the cellular dynamics of primary cancer cells in culture to uncover genetic causes of therapeutic insensitivity; and we will explore tumor-microenvironment interactions through in vivo and in vitro tissue reconstructions. Our goal in the next grant cycle is to bring several diagnostics and therapeutics to clinical development. In addition, we will establish a Cancer Education and Career Enhancement core that supports a continuum of learning for students, trainees, early career investigators and the Maine community oncology care providers. Our focus on complex genetics and functional genomics, the scale of our model creation and experimentation, and the integration of our diverse talents make the JAXCC a unique enterprise.

Public Health Relevance

OVERALL Genetic complexity and cellular heterogeneity are the greatest challenge to understanding and treating cancer. The Jackson Laboratory Cancer Center is focused on resolving this complexity through applying advanced computational and genomic approaches on novel organismal, cellular, and computational models of cancer, and by investigating the in vivo tumor-stromal-immune interactions. We translate our findings to the clinic through the provision of genetic and genomic technologies to key clinical collaborators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA034196-34
Application #
9854053
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
1997-08-01
Project End
2025-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
34
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Jackson Laboratory
Department
Type
DUNS #
042140483
City
Bar Harbor
State
ME
Country
United States
Zip Code
04609
Ye, Fengdan; Jia, Dongya; Lu, Mingyang et al. (2018) Modularity of the metabolic gene network as a prognostic biomarker for hepatocellular carcinoma. Oncotarget 9:15015-15026
Kong, Yang; Zhao, Lihong; Charette, Jeremy R et al. (2018) An FRMD4B variant suppresses dysplastic photoreceptor lesions in models of enhanced S-cone syndrome and of Nrl deficiency. Hum Mol Genet 27:3340-3352
Wu, Te-Chia; Xu, Kangling; Martinek, Jan et al. (2018) IL1 Receptor Antagonist Controls Transcriptional Signature of Inflammation in Patients with Metastatic Breast Cancer. Cancer Res 78:5243-5258
Muscat, Andrea M; Wong, Nicholas C; Drummond, Katharine J et al. (2018) The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection. Oncotarget 9:7844-7858
Kohar, Vivek; Lu, Mingyang (2018) Role of noise and parametric variation in the dynamics of gene regulatory circuits. NPJ Syst Biol Appl 4:40
NĂ©bor, Danitza; Graber, Joel H; Ciciotte, Steven L et al. (2018) Mutant KLF1 in Adult Anemic Nan Mice Leads to Profound Transcriptome Changes and Disordered Erythropoiesis. Sci Rep 8:12793
Linn, Sarah C; Mustonen, Allison M; Silva, Kathleen A et al. (2018) Nail abnormalities identified in an ageing study of 30 inbred mouse strains. Exp Dermatol :
Hosur, Vishnu; Farley, Michelle L; Burzenski, Lisa M et al. (2018) ADAM17 is essential for ectodomain shedding of the EGF-receptor ligand amphiregulin. FEBS Open Bio 8:702-710
Becker, Timothy; Lee, Wan-Ping; Leone, Joseph et al. (2018) FusorSV: an algorithm for optimally combining data from multiple structural variation detection methods. Genome Biol 19:38
Wang, Qianghu; Hu, Baoli; Hu, Xin et al. (2018) Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 33:152

Showing the most recent 10 out of 1156 publications